Skip to main content
SpringerLink
Log in

Monoamine oxidase inhibitors and the cheese effect

  • Original Articles
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

The behavior of inhibitors of monoamine oxidase-A (MAO-A) is considered in terms of the possibility of having an effective antidepressant that does not give rise to hypertensive interactions with dietary tyramine. Studies with punch-biopsy samples of human intestine and rat intestinal samples show MAO-A to be the predominant form of the enzyme in both species. Transport studies with everted rat intestinal preparations indicate that tyramine is extensively metabolized during transport through the intestine. Selective inhibition of MAO-A by clorgyline results in a large increase in the amount of unchanged tyramine transported, whereas selective inhibition of MAO-B with L-deprenyl (selegiline) has no significant effect. The behavior of reversible MAO-A inhibitors can significantly reduce, but not entirely eliminate, these effects on the intestinal metabolism of tyramine, but only if the inhibition is competitive in nature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tipton, K. F. 1989. Monoamine oxidase inhibitors as antidepressants. Pages 1–24,in Tipton, K. F. and Youdim, M. B. H. (eds.) Biochemical and Pharmacological Aspects of Depression. Taylor & Francis, London.

    Google Scholar 

  2. Blackwell, B. 1963. Hypertensive crisis due to monoamine oxidase inhibitors. Lancet (ii): 849–951.

    Google Scholar 

  3. Davis, D. S., Tasuhara, H., Boobis, A. R., and George, C. F. 1984. The effects of reversible and irreversible inhibitors of monoamine oxidase on tyramine deamination in dog intestine. Pages 443–448in Tipton, K. F., Dostert, P. and Strolin Benedetti, A. (eds.) Monoamine Oxidase and Disease. Academic Press, London.

    Google Scholar 

  4. Dostert, P. 1984. Myth and reality of the classical MAO inhibitors, reasons for seeking a new generation. Pages 487–497in Tipton, K. F., Dostert, P. and Strolin Benedetti, A. (eds.) Monoamine Oxidase and Disease. Academic Press, London.

    Google Scholar 

  5. Da Prada, M., Zürcher, G., Würthrich, I., and Haefely, W. E. 1988. Ontyramine, food beverages and the reversible MAO inhibitor moclobemide. J. Neural. Transmiss. 26 (Suppl.): 33–56.

    Google Scholar 

  6. Wheatley, A. M., and Tipton, K. 1987. Determination of tyramine in alcoholic and non-alcoholic beers by high performance liquid chromatography with electrochemical detection. J. Food. Biochem. 11:133–142.

    Google Scholar 

  7. Sen, N. P. 1969. Analysis and significance of tyramine in foods. J. Food. Sci. 34:22–26.

    Google Scholar 

  8. Dollery, C. T., Brown, M. J., Davies, D. S., and Strolin Benedetti, M. 1984. Pressor amines and monoamine oxidase inhibitors. Pages 429–441in Tipton, K. F., Dostert, P., and Strolin Benedetti, A. (eds.) Monoamine Oxidase and Disease. Academic Press, London.

    Google Scholar 

  9. Youdim, M. B. H., Finberg, J. P. M., and Tipton, K. F. 1988. Monoamine oxidase. Pages 119–192in Trendelenburg, U. and Weiner, N. (eds.) Handbook of Experimental Pharmacology, vol. 90. Springer Verlag, Berlin.

    Google Scholar 

  10. Tipton, K. F. 1985. Determination of monoamine oxidase. Meth. Find. Exp. Clin. Pharmacol. 7:361–367.

    Google Scholar 

  11. Hasan, F., McCrodden, J. M., Kennedy, N. P., and Tipton, K. F. 1988. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J. Neural. Transmiss. 26, (Suppl.): 1–9.

    Google Scholar 

  12. Strolin Benedetti, M., Boucher, T., Carlsson, A., and Fowler, C. J. 1983. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochem. Pharmacol. 32:47–52.

    PubMed  Google Scholar 

  13. Valoti, M., Tipton, K. F., and Sgaragli, G. P. 1992. Oxidative ring-coupling of tyrosine and its derivatives by purified rat intestinal peroxidase. Biochem. Pharmacol. 43:945–951.

    PubMed  Google Scholar 

  14. Rein, G., Glover, V., and Sandler, M. 1982. Multiple forms of phenolsulphotransferases in human tissues. Biochem. Pharmacol. 31:1893–1897.

    PubMed  Google Scholar 

  15. Biek, P. R., Kemmler, H., Henriot, S., and Tipton, K. F. 1988. Evidence for “local” gastroinestinal effects of MAO inhibition on metabolism and transport of tyramine in human subjects. Pharmacol. Res. Commun. 20:129–130.

    PubMed  Google Scholar 

  16. Mendis, N., Pare, C. M. B., Sandler, M., Glover, V., and Stern, G. M. 1981. Is the failure of (−)-deprenyl, a selective monoamine oxidase-B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacol. 73:87–90.

    Google Scholar 

  17. Pare, C. M. B. 1984. Clinical studies with monoamine oxidase inhibitors and tricyclic antidepressants. Pages 469–478in Tipton, K. F., Dostert, P. and Strolin Benedetti, A. (eds.) Monoamine Oxidase and Disease. Academic Press, London.

    Google Scholar 

  18. Erwin, V. G., and Deitrich, R. A. 1971. The labellingin vivo of monoamine oxidase by [14C]-pargyline: a tool for studying the synthesis of the enzyme. Mol. Pharmacol. 7:219–228.

    PubMed  Google Scholar 

  19. Della Corte, L., and Tipton, K. F. 1980. The turnover of the A- and B-forms of monoamine oxidase in rat liver. Biochem. Pharmacol. 29:811–815.

    Google Scholar 

  20. Neff, N. H., and Goridis, C. 1972. Neuronal monoamine oxidase: specific enzyme types and their rates of formation. Adv. Biochem. Psychopharmacol. 5:307–323.

    PubMed  Google Scholar 

  21. Callingham, B. A., Mazel, P. and Porter, J. C. 1985. Some properties of amine oxidase activities in the rat intestine. Br. J. Pharmacol. 86:553 P.

    Google Scholar 

  22. Arnett, C. D., Fowler, J. S., MarGregor, R. R., Schyler, D. J., Wolf, A. P., Langrström, B., and Haldin, C. J. 1987. Turnover of brain monoamine oxidase measureed in vivo by positron emission tomography using L-[14C] deprenyl. J. Neurochem. 49:522–527.

    PubMed  Google Scholar 

  23. Felner, A. E., and Waldmeier, P. C. 1979. Cumulative effects of irreversible MAO inhibitors in vivo. Biochem. Pharmacol. 28:995–1002.

    PubMed  Google Scholar 

  24. Waldmeier, P. C., Felner, A. E., and Tipton, K. F. 1983. The monoamine oxidase inhibiting properties of CGP 11305A. Eur. J. Pharmacol. 94:73–83.

    PubMed  Google Scholar 

  25. Tipton, K. F. and Fowler, C. J. 1984. The kinetics of monoamine oxidase inhibitors in relation to their clinical behaviour. Pages 27–40 in Tipton, K. F., Dostert, P. and Strolin Benedetti, A. (eds.) Monoamine Oxidase and Disease. Academic Press, London.

    Google Scholar 

  26. Da Prada, M., Kettler, R. M., Cesura, A. M., and Richards 1988. Reversible enzyme-activated monoamine oxidase inhibitors: new advances. Pharmacol. Res. Commun. 20, Suppl. 4:21–23.

    PubMed  Google Scholar 

  27. Anderson, M. C., Waldmeier, P. C., and Tipton, K. F. 1991. The inhibition of monoamine oxidase by brofaromine. Biochem. Pharmacol. 41:1871–1877.

    PubMed  Google Scholar 

  28. Da Prada, M., Kettler, R., Keller, H. H., Cesura, A. M., Richards, J. G., Saura Marti, J., Mugli-Maniglio, D., Wyss, P-C., Kyburz, E., and Imhof, R. 1990. From moclobemide to Ro 196327: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors J. Neural Transmiss. 29 (Suppl.): 279–292.

    Google Scholar 

  29. Callingham, B. A. 1989. Biochemical aspects of the pharmacology of moclobemide- The implications of animal studies. Br. J. Psychiat. 115 (Suppl. 6):53–60.

    Google Scholar 

  30. Knoll, J. 1989. The pharmacology of selegiline/(−) deprenyl. New aspects. Acta Neurol. Scand. 126:83–91.

    Google Scholar 

  31. Knoll, J. 1993. The pharmacological basis of the beneficial effects of (−) deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J. Neural Transmiss. (in press).

  32. Parkinson Study Group. 1989. Effect of deprenyl on the progression of disability in early Parkinson's disease. New. Engl. J. Med. 321:1364–1371.

    Google Scholar 

  33. Tetrud, J. W. and Langston, J. W. 1989. The effect of deprenyl on the natural history of Parkinson's disease. Science 245:519–522.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, Trinity College, Dublin 2, Ireland

    Mary C. Anderson, Farris Hasan, John M. McCrodden & Keith F. Tipton

Authors
  1. Mary C. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farris Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John M. McCrodden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keith F. Tipton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anderson, M.C., Hasan, F., McCrodden, J.M. et al. Monoamine oxidase inhibitors and the cheese effect. Neurochem Res 18, 1145–1149 (1993). https://doi.org/10.1007/BF00978365

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00978365

Key Words

Search

Navigation